It is estimated that almost two-thirds of cancer patients will receive radiation therapy (RT) during the course of their disease. This underscores the importance of constantly providing the healthcare system with advanced technology, and personalized, evidence-based approaches to treating cancer with RT. The University of Texas MD Anderson Cancer Center has a new head of the division of radiation oncology, who will also serve as the new chair of the department of radiation oncology.
Dr. Stephen Hahn is one of the most prominent radiation oncologists in the country. He will be joining MD Anderson on January 1, 2015, from his current position as the Henry K. Pancoast Professor and Chair of the department of radiation oncology in the University of Pennsylvania’s Perelman School of Medicine, which he has held since 2005. Dr. Bruce Minsky is the current interim division head and chair of the department.
Through Dr. Hahn’s contributions, the university became known as a leading institution for radiation oncology clinical practice and education. There he founded a cutting edge proton therapy center, and promoted more NIH-sponsored studies. During his time, a significant number of junior faculty members received substantial training and formation from the University of Pennsylvania, and have gone on to assume various national leadership positions. Dr. Hahn is also the newest addition to the American Society for Radiation Oncology’s (ASTRO’s) board of directors, effective this month.
He is an active physician of internal medicine, and a certified radiation and medical oncologist. His work concentrates on understanding the factors behind a tumor’s microenvironment, and how novel proton therapy can enhance today’s RT.
One of the more recently-launched developments in RT is the MRIdian™ system, which was created by ViewRay, Inc. It makes personalized cancer care more doable by combining real-time soft tissue visualization via magnetic resonance imaging (MRI) techniques with adjustable RT doses.